Robert L. Van Nostrand - Feb 27, 2024 Form 4 Insider Report for Intra-Cellular Therapies, Inc. (ITCI)

Role
Director
Signature
/s/ Lawrence J. Hineline, Attorney-in-fact
Stock symbol
ITCI
Transactions as of
Feb 27, 2024
Transactions value $
-$1,087,450
Form type
4
Date filed
2/28/2024, 07:41 PM
Previous filing
Jan 25, 2024
Next filing
Apr 1, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ITCI Common Stock Options Exercise $371K +20K +208.09% $18.56* 29.6K Feb 27, 2024 Direct
transaction ITCI Common Stock Sale -$702K -9.65K -32.59% $72.71 20K Feb 27, 2024 Direct F1
transaction ITCI Common Stock Sale -$757K -10.3K -51.85% $73.14 9.61K Feb 27, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ITCI Stock Option (right to buy) Options Exercise $0 -20K -100% $0.00* 0 Feb 27, 2024 Common Stock 20K $18.56 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.0016 to $73.00, inclusive. The reporting person undertakes to provide to the Issuer, any secuirty holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.0026 to $73.42, inclusive. The reporting person undertakes to provide to the Issuer, any secuirty holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F3 This option was granted on March 21, 2014 and will expire on March 21, 2024. All shares underlying this option have vested.